[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cg Oncology Inc (CGON)

Cg Oncology Inc (CGON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,947,251
  • Shares Outstanding, K 88,202
  • Annual Sales, $ 4,040 K
  • Annual Income, $ -161,000 K
  • EBIT $ -215 M
  • EBITDA $ -215 M
  • 60-Month Beta 0.31
  • Price/Sales 1,188.11
  • Price/Cash Flow N/A
  • Price/Book 4.39

Options Overview Details

View History
  • Implied Volatility 124.89% (+10.73%)
  • Historical Volatility 46.07%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 124.89% on 06/05/26
  • IV Low 50.89% on 08/18/25
  • Expected Move (DTE 12) 5.36 (9.97%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 5,280
  • Volume Avg (30-Day) 3,190
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 47,144
  • Open Int (30-Day) 46,600
  • Expected Range 48.37 to 59.08

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.70
  • Number of Estimates 6
  • High Estimate $-0.67
  • Low Estimate $-0.73
  • Prior Year $-0.54
  • Growth Rate Est. (year over year) -29.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.52 +0.37%
on 06/05/26
75.50 -28.85%
on 05/14/26
-13.46 (-20.03%)
since 05/05/26
3-Month
53.52 +0.37%
on 06/05/26
75.50 -28.85%
on 05/14/26
-6.65 (-11.02%)
since 03/05/26
52-Week
23.65 +127.15%
on 08/11/25
75.50 -28.85%
on 05/14/26
+27.09 (+101.73%)
since 06/05/25

Most Recent Stories

More News
CG Oncology to Present at Upcoming Investor Conferences in June

DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations...

CGON : 53.72 (-4.23%)
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference

CG Oncology (NASDAQ:CGON) executives used an RBC Capital Markets fireside chat to outline recent clinical data for cretostimogene, the company’s investigational therapy for non-muscle invasive bladder...

CGON : 53.72 (-4.23%)
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award

Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the development of outstanding clinical cancer research to improve the treatment of NMIBC Last year’s...

CGON : 53.72 (-4.23%)
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively - High-Grade - EFS in the overall intention-to-treat...

CGON : 53.72 (-4.23%)
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears

CG Oncology (NASDAQ:CGON) executives said the company remains on track to complete a rolling biologics license application for cretostimogene in BCG-unresponsive high-risk non-muscle invasive bladder cancer...

CGON : 53.72 (-4.23%)
CGON's Billion-Dollar Cash Pile Masking the Absence of a Commercial Product

Barchart Research What to Expect from CGON Earnings CGON Generated May 11, 2026 Current Price $69.32 EPS Estimate $$-0.60 Consensus Rating Strong Buy Average Move 5.32% CGON's Billion-Dollar Cash Pile...

CGON : 53.72 (-4.23%)
CG Oncology’s Presence at American Urological Association (AUA) Annual Meeting Underscores its Strong Commitment to NMIBC

- First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented - - Visit CG Oncology at booth...

CGON : 53.72 (-4.23%)
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates

Following alignment discussions with FDA, BLA completion for HR BCG-unresponsive NMIBC is expected fourth quarter 2026  PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant...

CGON : 53.72 (-4.23%)
CG Oncology to Present at Upcoming Investor Conferences in May

DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer,...

CGON : 53.72 (-4.23%)
CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates

PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026 CORE-008 Cohort CX Phase 2 first results of combination...

CGON : 53.72 (-4.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 59.08
2nd Resistance Point 57.93
1st Resistance Point 55.82
Last Price 53.72
1st Support Level 52.57
2nd Support Level 51.42
3rd Support Level 49.31

See More

52-Week High 75.50
Fibonacci 61.8% 55.69
Last Price 53.72
Fibonacci 50% 49.58
Fibonacci 38.2% 43.46
52-Week Low 23.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.